GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005125826 | Esophagus | HGIN | protein polymerization | 66/2587 | 297/18723 | 4.96e-05 | 1.19e-03 | 66 |
GO:003004120 | Esophagus | HGIN | actin filament polymerization | 40/2587 | 191/18723 | 4.29e-03 | 3.82e-02 | 40 |
GO:0051258111 | Esophagus | ESCC | protein polymerization | 183/8552 | 297/18723 | 1.94e-08 | 3.75e-07 | 183 |
GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
GO:000815420 | Esophagus | ESCC | actin polymerization or depolymerization | 130/8552 | 218/18723 | 2.19e-05 | 1.88e-04 | 130 |
GO:0030041110 | Esophagus | ESCC | actin filament polymerization | 114/8552 | 191/18723 | 6.46e-05 | 4.92e-04 | 114 |
GO:005125822 | Liver | HCC | protein polymerization | 182/7958 | 297/18723 | 4.17e-11 | 1.58e-09 | 182 |
GO:000701522 | Liver | HCC | actin filament organization | 252/7958 | 442/18723 | 3.83e-10 | 1.25e-08 | 252 |
GO:000815422 | Liver | HCC | actin polymerization or depolymerization | 130/7958 | 218/18723 | 2.31e-07 | 4.14e-06 | 130 |
GO:003004122 | Liver | HCC | actin filament polymerization | 116/7958 | 191/18723 | 2.66e-07 | 4.68e-06 | 116 |
GO:000717312 | Lung | AIS | epidermal growth factor receptor signaling pathway | 29/1849 | 108/18723 | 3.99e-07 | 3.23e-05 | 29 |
GO:003812712 | Lung | AIS | ERBB signaling pathway | 30/1849 | 121/18723 | 1.60e-06 | 9.91e-05 | 30 |
GO:000717322 | Lung | MIAC | epidermal growth factor receptor signaling pathway | 20/967 | 108/18723 | 5.82e-07 | 9.33e-05 | 20 |
GO:003812722 | Lung | MIAC | ERBB signaling pathway | 20/967 | 121/18723 | 3.70e-06 | 3.88e-04 | 20 |
GO:0007015112 | Thyroid | PTC | actin filament organization | 225/5968 | 442/18723 | 3.76e-17 | 3.44e-15 | 225 |
GO:0051258113 | Thyroid | PTC | protein polymerization | 154/5968 | 297/18723 | 5.35e-13 | 2.66e-11 | 154 |
GO:000815426 | Thyroid | PTC | actin polymerization or depolymerization | 117/5968 | 218/18723 | 1.85e-11 | 7.21e-10 | 117 |
GO:003004125 | Thyroid | PTC | actin filament polymerization | 99/5968 | 191/18723 | 7.40e-09 | 1.85e-07 | 99 |
GO:0007015210 | Thyroid | ATC | actin filament organization | 227/6293 | 442/18723 | 5.96e-15 | 3.85e-13 | 227 |
GO:005125829 | Thyroid | ATC | protein polymerization | 159/6293 | 297/18723 | 9.33e-13 | 3.96e-11 | 159 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0451022 | Lung | AIS | Focal adhesion | 57/961 | 203/8465 | 3.17e-11 | 3.43e-09 | 2.19e-09 | 57 |
hsa0510023 | Lung | AIS | Bacterial invasion of epithelial cells | 25/961 | 77/8465 | 6.03e-07 | 2.44e-05 | 1.56e-05 | 25 |
hsa0152122 | Lung | AIS | EGFR tyrosine kinase inhibitor resistance | 20/961 | 79/8465 | 3.92e-04 | 3.85e-03 | 2.47e-03 | 20 |
hsa0401221 | Lung | AIS | ErbB signaling pathway | 21/961 | 85/8465 | 4.06e-04 | 3.87e-03 | 2.47e-03 | 21 |
hsa015222 | Lung | AIS | Endocrine resistance | 22/961 | 98/8465 | 1.21e-03 | 9.02e-03 | 5.77e-03 | 22 |
hsa0472221 | Lung | AIS | Neurotrophin signaling pathway | 25/961 | 119/8465 | 1.59e-03 | 1.05e-02 | 6.72e-03 | 25 |
hsa0521421 | Lung | AIS | Glioma | 17/961 | 75/8465 | 3.76e-03 | 2.00e-02 | 1.28e-02 | 17 |
hsa0522521 | Lung | AIS | Hepatocellular carcinoma | 31/961 | 168/8465 | 4.11e-03 | 2.15e-02 | 1.38e-02 | 31 |
hsa0522022 | Lung | AIS | Chronic myeloid leukemia | 17/961 | 76/8465 | 4.34e-03 | 2.23e-02 | 1.43e-02 | 17 |
hsa0492621 | Lung | AIS | Relaxin signaling pathway | 25/961 | 129/8465 | 4.95e-03 | 2.47e-02 | 1.58e-02 | 25 |
hsa0493521 | Lung | AIS | Growth hormone synthesis, secretion and action | 23/961 | 120/8465 | 7.85e-03 | 3.58e-02 | 2.29e-02 | 23 |
hsa0491522 | Lung | AIS | Estrogen signaling pathway | 25/961 | 138/8465 | 1.18e-02 | 4.83e-02 | 3.09e-02 | 25 |
hsa0451032 | Lung | AIS | Focal adhesion | 57/961 | 203/8465 | 3.17e-11 | 3.43e-09 | 2.19e-09 | 57 |
hsa0510033 | Lung | AIS | Bacterial invasion of epithelial cells | 25/961 | 77/8465 | 6.03e-07 | 2.44e-05 | 1.56e-05 | 25 |
hsa0152132 | Lung | AIS | EGFR tyrosine kinase inhibitor resistance | 20/961 | 79/8465 | 3.92e-04 | 3.85e-03 | 2.47e-03 | 20 |
hsa0401231 | Lung | AIS | ErbB signaling pathway | 21/961 | 85/8465 | 4.06e-04 | 3.87e-03 | 2.47e-03 | 21 |
hsa0152211 | Lung | AIS | Endocrine resistance | 22/961 | 98/8465 | 1.21e-03 | 9.02e-03 | 5.77e-03 | 22 |
hsa0472231 | Lung | AIS | Neurotrophin signaling pathway | 25/961 | 119/8465 | 1.59e-03 | 1.05e-02 | 6.72e-03 | 25 |
hsa052143 | Lung | AIS | Glioma | 17/961 | 75/8465 | 3.76e-03 | 2.00e-02 | 1.28e-02 | 17 |
hsa0522531 | Lung | AIS | Hepatocellular carcinoma | 31/961 | 168/8465 | 4.11e-03 | 2.15e-02 | 1.38e-02 | 31 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SHC3 | SNV | Missense_Mutation | | c.737N>T | p.Ala246Val | p.A246V | Q92529 | protein_coding | deleterious(0) | possibly_damaging(0.843) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SHC3 | SNV | Missense_Mutation | | c.821N>A | p.Pro274His | p.P274H | Q92529 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SHC3 | SNV | Missense_Mutation | rs756796666 | c.1273N>A | p.Val425Ile | p.V425I | Q92529 | protein_coding | tolerated(0.23) | possibly_damaging(0.498) | TCGA-AX-A05Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SHC3 | SNV | Missense_Mutation | | c.767C>G | p.Ala256Gly | p.A256G | Q92529 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
SHC3 | SNV | Missense_Mutation | novel | c.496C>A | p.Leu166Met | p.L166M | Q92529 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
SHC3 | SNV | Missense_Mutation | novel | c.1123N>C | p.Lys375Gln | p.K375Q | Q92529 | protein_coding | tolerated(0.54) | benign(0.131) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SHC3 | SNV | Missense_Mutation | rs763004278 | c.710N>A | p.Arg237Gln | p.R237Q | Q92529 | protein_coding | deleterious(0.04) | benign(0.041) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SHC3 | SNV | Missense_Mutation | rs764795129 | c.1655N>T | p.Thr552Met | p.T552M | Q92529 | protein_coding | deleterious(0.04) | probably_damaging(0.981) | TCGA-AX-A1C8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unspecific | Carboplatin | SD |
SHC3 | SNV | Missense_Mutation | novel | c.1569N>T | p.Lys523Asn | p.K523N | Q92529 | protein_coding | deleterious(0) | possibly_damaging(0.497) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
SHC3 | SNV | Missense_Mutation | novel | c.1108N>T | p.Ala370Ser | p.A370S | Q92529 | protein_coding | tolerated(0.62) | benign(0.057) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |